Journal
BIOLOGICAL & PHARMACEUTICAL BULLETIN
Volume 33, Issue 2, Pages 329-333Publisher
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/bpb.33.329
Keywords
Erigeron annuus; caffeoylquinic acid; advanced glycation end product; aldose reductase; diabetic complication
Categories
Funding
- Korea Institute of Oriental Medicine (KIOM) [K09030]
- National Research Council of Science & Technology (NST), Republic of Korea [K09030] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Ask authors/readers for more resources
In our ongoing project directed toward the discovery of novel treatments for diabetic complications from herbal medicines, sixteen compounds including three caffeoylquinic acids and four flavonoids were isolated from an EtOAc-soluble extract of the stems and leaves of Erigeron annuus. All the isolates were evaluated in vitro for inhibitory activity on the formation of advanced glycation end products (AGEs) and rat lens aldose reductase (RLAR). Of these, 3,5-di-O-caffeoyl-epi-quinic acid (3) exhibited the most potent inhibitory activity in both the AGEs and aldose reductase (AR) assays. Compound 3 markedly reduced AGEs-bovin serum albumin (BSA) cross-linking in a dose-dependent manner. Furthermore, opacity of lenses was significantly prevented when they were treated with 3 in an ex vivo experiment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available